Graphical Abstract Highlights d DIPG is vulnerable to transcriptional disruption via BRD4 or CDK7 blockade d Panobinostat-resistant DIPG cells retain susceptibility to CDK7 blockade with THZ1 d Super-enhancer analyses indicate an early oligodendroglial precursor cell of origin d Chromatin analyses reveal EPH receptor signaling as crucial to DIPG invasion SUMMARY
In Brief Nagaraja et al. show that diffuse intrinsic pontine glioma (DIPG), a fatal pediatric tumor, is vulnerable to BRD4 or CDK7 blockade, and inhibition of either synergizes with HDAC inhibition to block growth of DIPG. Super-enhancer analysis of DIPG suggests oligodendroglial precursors as the cell of origin.
INTRODUCTION
Diffuse intrinsic pontine glioma (DIPG) is a universally fatal CNS cancer representing the leading cause of brain tumor-related death in children (Ostrom et al., 2015) . As complete resection is not possible and conventional chemotherapy is ineffective, the standard of care remains radiation alone. Recent genomic studies have revealed that 80% of DIPG tumors exhibit a characteristic mutation of lysine 27 to methionine (K27M) in genes encoding histone H3.3 and H3.1 and subsequent aberrant transcription (Bender et al., 2013; Chan et al., 2013; Khuong-Quang et al., 2012; Lewis et al., 2013; Schwartzentruber et al., 2012; Taylor et al., 2014; Wu et al., 2012) . The H3K27M mutation results in perturbation of Polycomb repressive complex 2 (PRC2) function, resulting in global hypomethylation of K27 in all H3 variants (Lewis et al., 2013; Bender et al., 2013; Wu et al., 2012) and broad epigenetic dysregulation believed to be central to DIPG oncogenesis (Bender et al., 2013; Chan et al., 2013; Lewis et al., 2013; Venneti et al., 2013; Funato et al., 2014) .
We previously identified panobinostat, a multiple histone deacetylase (HDAC) inhibitor, as an effective agent against patient-derived DIPG cell cultures and xenograft models (Grasso et al., 2015) . Panobinostat restored H3K27me3 (Grasso et al., 2015) , likely via disruption of aberrant PRC2 inhibition through Significance Diffuse intrinsic pontine glioma (DIPG) is a universally fatal pediatric cancer. A histone-3 K27M mutation affects 80% of DIPGs and drives aberrant transcription. Here, we demonstrate that transcriptional disruption achieved by targeting either BRD4 or CDK7 is a promising strategy for DIPG, particularly in combination with HDAC inhibition. Analyses of key regulatory elements called super-enhancers in DIPG underscores cell-identity genes, supporting the hypothesis that DIPG arises from a precursor cell in the oligodendroglial lineage and highlighting several unexpected gene families that prove functionally important to DIPG pathobiology. Taken together, the findings presented here identify targets for therapy of this devastating cancer.
polyacetylation of nearby residues and subsequent blockade of K27M-PRC2 interactions (Brown et al., 2014) . Large transcriptional changes were observed with panobinostat treatment, including rescue of many gene expression aberrations associated with the K27M mutation (Grasso et al., 2015) . However, DIPG resistance to HDAC inhibition ultimately develops (Grasso et al., 2015) , highlighting the importance of advancing drug combinations or identifying alternative strategies to more potently disrupt oncogenic gene expression.
An effective strategy in many preclinical models of malignancy with transcriptional dysregulation has been to disrupt efficient RNA polymerase II (RNAPII) transcription through inhibition of chromatin readers and writers (Posternak and Cole, 2016; Hagenbuchner and Ausserlechner, 2016) . This has commonly been done through BET (bromodomain and extra-terminal) protein inhibition, targeting family member BRD4 (Lové n et al., 2013; Delmore et al., 2011; Dawson et al., 2011; Filippakopoulos and Knapp, 2014; Mertz et al., 2011; Zuber et al., 2011; Coudé et al., 2015; Picaud et al., 2015; Sengupta et al., 2015a Sengupta et al., , 2015b Shahbazi et al., 2016; Zhang et al., 2016; Bid et al., 2016) , a key activator of RNAPII transcription at active chromatin marks (Jang et al., 2005; LeRoy et al., 2008; Rahman et al., 2011) . An alternative target is CDK7, a member of the cyclin-dependent kinase family involved in regulation of RNAPII phosphorylation, controlling transcriptional initiation, pausing, and elongation (Fisher and Morgan, 1994; Glover-Cutter et al., 2009; Larochelle et al., 2007 Larochelle et al., , 2012 Rossignol et al., 1997; Serizawa et al., 1995) . THZ1 is a highly specific CDK7 inhibitor effective in preclinical models for malignancies with transcription factor dysregulation, such as T cell acute lymphoblastic leukemia , small cell lung carcinoma , neuroblastoma , and triple-negative breast cancer . In this study, we investigate the efficacy of single and combinatorial targeting of transcription in DIPG, and characterize gene expression and active chromatin elements, in an effort to identify core genes regulating DIPG oncogenesis.
RESULTS

Bromodomain Inhibition Disrupts In Vitro DIPG Cell
Viability and In Vivo Tumor Growth JQ1, a tool compound, is a thoroughly studied inhibitor of bromodomain activity with efficacy in a number of preclinical models (Filippakopoulos and Knapp, 2014; Mertz et al., 2011; Zuber et al., 2011; Bid et al., 2016; Coudé et al., 2015; Picaud et al., 2015; Sengupta et al., 2015a Sengupta et al., , 2015b Shahbazi et al., 2016; Zhang et al., 2016) . Many of the cancers studied to date that demonstrate sensitivity to transcriptional disruption exhibit MYC or MYCN amplification or overexpression. A subset of DIPGs exhibits MYC/MYCN amplification, with MYCN amplification observed chiefly in tumors that do not exhibit the H3K27M mutation and MYC amplification observed in H3K27M mutant tumors (Buczkowicz et al., 2014) . A larger subset exhibits high levels of MYC/MYCN expression (Grasso et al., 2015; Figure S1A) . However, transcriptional dysregulation in DIPG is chiefly driven by the H3K27M mutation (Bender et al., 2013; Chan et al., 2013; Lewis et al., 2013; Venneti et al., 2013; Funato et al., 2014) . Given this well-established aberrancy, we hypothesized that DIPG may be vulnerable to transcriptional disruption. Eight patient-derived DIPG cultures and one pediatric cortical glioblastoma culture (SU-pcGBM2) were used in this study; seven of the eight DIPGs exhibit the H3K27M mutation and one is histone wild-type (WT) (H3.3K27M: SU-DIPG-VI, SU-DIPG-XIII-P, SU-DIPG-XVII, SU-DIPG-XXV, SF7761, and JHH-DIPG1; H3.1K27M: SU-DIPG-IV; H3WT and MYCN amplified: VUMC-DIPG-10; Tables S1 and S2). SU-pcGBM2 is histone-3 WT and exhibits a TP53 mutation and EGFR amplification (Table  S1; Venkatesh et al., 2015) . To confirm and extend the observation that BET inhibition reduces DIPG cell viability (Taylor et al., 2015) , we treated these patient-derived cell cultures with a range of concentrations of JQ1 and observed a dose-dependent reduction in DIPG cell viability across all cell cultures, particularly at later time points (72-hr half-maximal inhibitory concentration [IC 50 ] > 1 mM in most cultures; 6-day IC 50 median 0.35 mM, range 0.076-2.06 mM; Figures 1A and S1B). Interestingly, while the H3WT culture VUMC-DIPG-10 responded to JQ1 treatment similarly to other DIPG cultures, the H3WT pediatric glioblastoma cell culture SU-pcGBM2 showed minimal vulnerability to JQ1 treatment ( Figure 1A ). While few conclusions can be drawn from the limited number of H3WT DIPG cultures available for study, H3WT DIPGs may be vulnerable to transcriptional disruption when carrying an MYC/MYCN amplification, whereas H3K27M DIPGs harbor sensitivity due to the H3K27M oncogenic effect on transcription. Time-course tracking of JQ1-treated DIPG cells indicated that the inhibitory effect of JQ1 against DIPG cells is more cytostatic than cytocidal (Figures 1B and (B) DIPG cells treated with JQ1 at indicated concentrations or 0.1% DMSO control. Cell viabilities measured at 0, 3, and 6 days of treatment and normalized to day-0 values (n = 3 wells per data point). (C) 5-Ethynyl-2 0 -deoxyuridine (EdU) incorporation of DIPG cells treated with 0.1% DMSO or 1 mM JQ1 for 48 hr. (D) Annexin V (AV)/DAPI staining of DIPG cells treated with 0.1% DMSO or 1 mM JQ1 for 72 hr. (E) DIPG cells infected either of two clones of shBRD4 (shBD4-1 or shBRD4-2) or control construct (shCtrl) lentivirus. Knockdown efficiency by qRT-PCR (left, n = 2) or western blot (right). (F) SU-DIPG-VI cells (left) and SF7761 cells (right) infected with lentivirus expressing shBRD4-1, shBRD4-2, or shCtrl (control) were implanted in the brainstem at P2 and allowed to engraft for 4 weeks. Tumor growth of DIPG xenografts were then monitored by IVIS (in vivo imaging system) imaging at weeks 0, 1, 3, 5, and 8. For SU-DIPG-VI: shCtrl n = 7 mice, shBRD4-1 n = 5 mice, shBRD4-2 n = 6 mice. For SF7761: shCtrl n = 5 mice, shBRD4-1 n = 4 mice, shBRD4-2 n = 3 mice. Data shown normalized to week-0 value for each group; error bars denote SEM. *p < 0.5, **p < 0.01 (two-tailed Student's t test). (G) Survival curves of xenografted mice implanted with SU-DIPG-VI cells infected with lentivirus expressing shBRD4-1, shBRD4-2, or shCtrl construct. Log-rank analyses were performed to calculate the p value comparing shCtrl and shBRD4 groups (shCtrl n = 7 mice, shBRD4-1 n = 5 mice, shBRD4-2 n = 6 mice). Data are shown as mean ± SD unless otherwise indicated. FACS analyses shown in bar plots (C and D) illustrate one representative experiment. See also Figure S1 and Tables S1-S3. (legend continued on next page) S1C). Indeed, fluorescence-activated cell sorting (FACS) analyses showed inhibition of cell proliferation ( Figure 1C ) and only a moderate increase in apoptosis following JQ1 exposure ( Figure 1D ).
We next tested the effect of bromodomain inhibitor drugs presently in clinical development, iBET762 (Mirguet et al., 2013) and OTX015 (Coudé et al., 2015) . At 72 hr of treatment, DIPG cells largely demonstrated IC 50 values greater than 1 mM, suggesting that these drugs are not sufficiently potent for clinical translation, but showed a modest dose-dependent inhibition of cell viability at 6 days of treatment (Figures S1D and S1E). Brain penetration studies indicated that OTX015 levels achieved in brain (150 nM; Table S3 ) following standard in vivo dosing are only a fraction of the 72-hr IC 50 for DIPG cells. While these relatively high IC 50 values and insufficient brain penetration indicate that these specific agents lack the potency necessary for clinical translation in DIPG, the data suggest that DIPG cells may be sensitive to loss of bromodomain activity in principle.
To determine the therapeutic potential of effective bromodomain inhibition, we tested the effects of BRD4 loss in DIPG orthotopic xenograft models. Patient-derived DIPG cell cultures expressing firefly luciferase, SU-DIPG-VI-luc and SF7761-luc (Grasso et al., 2015; Hashizume et al., 2014) , were infected with a vector expressing either short hairpin RNA (shRNA) targeting BRD4 or a non-targeting control ( Figure 1E ). BRD4 knockdown resulted in decreased proliferation and slowed DIPG cell growth in vitro, and did not alter luciferase expression or in vivo engraftment (Figures S1F-S1I). Accordingly, mice xenografted with DIPG cells expressing BRD4 shRNA showed a stark reduction in tumor growth and improved survival relative to mice xenografted with cells expressing the non-targeting control ( Figures 1F and 1G ). BRD4 function thus appears to be necessary for DIPG growth in vivo, underscoring the potential that effective bromodomain inhibition holds for DIPG therapy when appropriate pharmacological agents become available.
CDK7 Inhibition with THZ1 Impairs DIPG Growth
We next sought to determine whether alternative methods of disrupting transcription could be effective in DIPG. We found that THZ1 robustly reduced DIPG cell viability in a dose-dependent manner, with a median 72-hr IC 50 of 56 nM in eight patientderived DIPG cell cultures tested (range 28-533 nM) ( Figures  2A, 2B , and S2A), consistent with IC 50 concentrations reported in other malignant models Jiang et al., 2016) . Similar to bromodomain inhibition, the SU-pcGBM2 culture was somewhat less vulnerable to CDK7 inhibition (IC 50 640 nM). Patient-derived DIPG cells exhibited robustly decreased proliferation ( Figure 2C ) and increased apoptosis ( Figure 2D ) following THZ1 exposure. Consistently, we observed loss of RNAPII CTD phosphorylation 24 hr after THZ1 treatment ( Figure 2E ), indicating effective CDK7 inhibition. Disruption of RNAPII transcription through CDK7 inhibition thus appears to potently disrupt DIPG cell viability.
To determine whether THZ1 could be used for brain tumors, we quantified brain penetration and observed an average THZ1 brain parenchymal concentration of 13.7 ng/g or approximately 24 nM following intraperitoneal dosing, and approximately 600 nM following intravenous dosing (Table S3 ). Given the relative potency of the agent against DIPG, we tested the efficacy of THZ1 in two patient-derived orthotopic xenograft models, SU-DIPG-VI and SU-DIPG-XIII-FL (derived from the frontal lobe DIPG metastasis in subject SU-DIPG-XIII). Our ability to administer THZ1 intravenously was limited by tail-vein sclerosis to only 1 week, but we observed proof-of-principle reduction in DIPG xenograft growth ( Figure S2B ). Similar to epigenetic modifying agents studied in previous publications (Tang et al., 2014; Grasso et al., 2015) , we observed an increase in relative luciferase activity with in vitro THZ1 treatment ( Figure S2C ), suggesting that our in vivo observation of reduced luciferase levels was not due to a reduction in transcription of luciferase but rather to a decrease in tumor burden.
Next, we turned to intraperitoneal dosing of THZ1 in a particularly aggressive patient-derived DIPG xenograft model (SU-DIPG-XIII-P*). THZ1 administration resulted in a significant but modest (20%) increase in median survival when compared with vehicle-treated control mice ( Figure 2F ). Taken together, these data suggest that DIPG is vulnerable to CDK7 inhibition both in vitro and in vivo, with better brain tissue delivery required for optimal clinical translation.
Combinatorial Transcriptional Therapy in DIPG
Our previous work showed that the Food and Drug Administration-approved drug panobinostat exhibits a degree of preclinical benefit against DIPG (Grasso et al., 2015) , and it is presently in a phase I clinical trial for children with DIPG (NCT02717455). A recent study similarly demonstrated a modest benefit of panobinostat in a murine DIPG model evidenced by reduced tumor cell proliferation (Hennika et al., 2017) . We hypothesized that stronger disruption of DIPG cell viability may come from combinatorial treatment with both HDAC inhibition and disruption of RNAPIIdependent transcription. HDAC inhibition together with JQ1 or THZ1 synergistically reduced cell viability across multiple DIPG cell cultures ( Figures 3A, 3B , S3A, and S3B), and proved more effective in inhibiting proliferation and inducing apoptosis (Figures S3D and S3E) . Synergistic inhibition of cell viability with JQ1 and THZ1 combinatorial treatment was also observed ( Figure S3C ).
As treatment with panobinostat ultimately results in resistance (Grasso et al., 2015) , we hypothesized that transcription in these resistant cells may be disrupted through bromodomain or CDK7 inhibition. We generated panobinostat-resistant cells as previously described (Grasso et al., 2015) and found that panobinostat-resistant cells retained submicromolar sensitivity to THZ1 ( Figure 3C ). In contrast, cells resistant to panobinostat also (F) SU-DIPG-XIII-P* cells were xenografted to the pons at postnatal day 43 (P43) and allowed to engraft for 10 days prior to treatment. SU-DIPG-XIII-P* represents a particularly aggressive subclone of the SU-DIPG-XIII-P culture. Mice were treated with THZ1 at 10 mg/kg intraperitoneally twice daily. Log-rank analyses were performed to calculate the p value, comparing vehicle-treated and THZ1-treated groups (vehicle n = 4 mice, THZ1 n = 4 mice). Data are shown as mean ± SD unless otherwise indicated. FACS analysis shown in bar plots (C and D) for one representative experiment. See also Figure S2 and Table S3 .
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To better understand the interaction of these therapies, we characterized the genes disrupted by panobinostat, JQ1, and THZ1. We performed RNA sequencing (RNA-seq) after 24 hr of treatment with panobinostat, THZ1, or JQ1 alone or in combination. As in other malignant models Christensen et al., 2014; Kwiatkowski et al., 2014) , we observed global downregulation of active transcripts with THZ1 treatment (Figure S3F ) and downregulation of specific subsets of genes by JQ1 ( Figure S3F ; Delmore et al., 2011; Dawson et al., 2011) .
We then examined the top target genes of panobinostat, JQ1, and THZ1. Unsupervised hierarchical clustering revealed that panobinostat and JQ1 caused similar transcriptional changes, downregulating many of the same genes and clustering apart from cells treated with THZ1 ( Figures 3D and 3E) , thus explaining the shared resistance described above. By contrast, the top targets of THZ1 showed very little disruption with panobinostat or JQ1. Combinatorial treatment of panobinostat with JQ1 or THZ1 resulted in the greatest downregulation of each of these genes, with changes consistent with an additive effect of single-agent treatments. Thus, panobinostat and JQ1 may synergistically disrupt cell viability by creating stronger inhibition at a common set of genes than either single treatment. In contrast, panobinostat and THZ1 preferentially disrupt distinct sets of genes and may achieve synergy by disrupting a larger number of genes in combination than in single treatment.
To further understand the mechanisms mediating cell viability disruption, we performed gene ontology analysis on the top downregulated target genes of each drug ( Figure S3G ). THZ1treated cells showed preferential disruption of genes related to transcription and gene regulation, such as ETS1, ELF4, MGA, SOX10, and HES5. In contrast, both JQ1 and panobinostat disrupted key regulators of nervous system development, including NTRK3, LINGO1, ASCL1, SYT4, SYT17, MYT1, MYRF, and SALL3. In addition, both drugs disrupted genes that enriched for synapse organization and structure, with one panobinostat target being NLGN3, a key mechanism mediating neuronal activity-regulated glioma growth (Venkatesh et al., 2015) .
Together, these data show that targeting RNAPII-dependent transcription in conjunction with HDAC inhibition is more effective than either drug alone. Panobinostat-resistant cells retain sensitivity to THZ1, suggesting that CDK7 blockade together with HDAC inhibition may be a promising combination strategy for DIPG.
Identification of Super-enhancers in DIPG Reveals
Potential Therapeutic Targets and Cell-Identity Genes CDK7 and bromodomain inhibition both preferentially disrupt transcription at genes associated with super-enhancers (Lové n et al., 2013; Chipumuro et al., 2014; Christensen et al., 2014; Jiang et al., 2016) . Super-enhancers (SEs) are large clusters of enhancer elements displaying unusually high levels of activating marks, such as H3K27 acetylation (H3K27Ac), and transcription complex subunit binding, including RNAPII and BRD4 (Whyte et al., 2013) . The genes associated with SEs in cancer are enriched for drivers of oncogenic state as well as normal regulators of cell identity (Lové n et al., 2013; Hnisz et al., 2013) . Given the effectiveness of these therapies in inhibiting DIPG growth, we characterized the SE landscape of DIPG through H3K27Ac chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) in three DIPG H3.3K27M cultures (SU-DIPG-VI, SU-DIPG-XIII-P, and SU-DIPG-XVII) and one H3.1K27M mutant (SU-DIPG-IV) culture, and annotated each SE with its nearest transcription start site (TSS) (Figures 4A and 4B; for full list see Table S4 ). A number of the genes associated with SEs were markers of undifferentiated neural cell state, including SOX2 and NES. Many were genes of oligodendroglial lineage identity, including genes classically associated with oligodendrocyte precursor cells such as SOX10, CSPG4 (also known as NG2), NKX2.2, PDGFRA, OLIG2, and LINGO1, as well as genes expressed by oligodendroglial lineage cells during differentiation such as OLIG1, MYRF, MYT1, and MBP. These findings lend support to the notion that DIPG may originate from a precursor cell early in differentiation in the oligodendroglial lineage (Monje et al., 2011; Tate et al., 2015) .
To identify commonalities in DIPG biology, we considered shared SEs between four cultures, defined as overlapping SEs present in at least three of the cultures studied. When linked to gene expression levels quantified by RNA-seq ( Figure 4C ), we observed that the genes associated with these shared SEs represent a set of transcripts highly expressed in both culture and in previously published primary tissue, likely identifying a core set of genes controlling both DIPG cell identity and malignant state. We then performed an analysis using the Genomic Regions Enrichment of Annotations Tool (GREAT) (McLean et al., 2010) on all shared SE regions ( Figure 4D ) and observed enrichment for regulators of CNS differentiation and neurogenesis, as well as genes controlling axon guidance and neuron projection morphogenesis.
Regulators of signal transduction were also heavily enriched. As SEs in malignant cells often mark key pathways maintaining Figure S3 . oncogenic state, we examined the pathways associated with these genes using PANTHER analysis (Mi et al., 2016;  Figure 5A ). This may represent a key list for developing targeted therapy in DIPG. Consistent with this notion, we observed enrichment for a number of pathways previously described as dysregulated and important to DIPG biology, including NOTCH (Taylor et al., 2015) , Hedgehog (Monje et al., 2011) , and PDGF (plateletderived growth factor) (Paugh et al., 2013) . These signaling pathways enriched for common downstream kinases (MAPK1, MAPK3K1, MAP3K2, MAPK8, MAPK11, MAPAPK2, PRKCA, PRKCD, PRKCE, and PRKCZ). As EGF (epidermal growth factor), FGF (fibroblast growth factor), Ras, Hedgehog, and others of these signaling pathways converge upon MAPK/ERK and mTOR signaling (Cristea and Sage, 2016; Switon et al., 2017; Kim et al., 2016; McCubrey et al., 2016) , we hypothesized that targeting these downstream pathways may be an effective way to simultaneously disrupt multiple oncogenic pathways. Cell viability was disrupted in two out of four cell cultures when treated with ERK1/2 inhibitor SCH772984 (Morris et al., 2013) and all four cell cultures with dual mTORC1/2 inhibitor AZD8055 (Chresta et al., 2010) at submicromolar concentrations (AZD8055: median IC 50 0.12 mM; Figure 5B ).
We found a large number of potassium (K + ) channel genes associated with SEs in DIPG ( Figure 5C ). Preclinical work in lung and breast cancers (Sun et al., 2016) , as well as medulloblastoma , has shown targeting of K + channels to be therapeutically effective. As we observed a large number K + channels across a variety of channel families (voltage-gated, inward-rectifying, two-pore, Ca 2+ -activated) to be expressed in DIPG, we targeted all K + channels using 10 mM cesium chloride (CsCl). CsCl specifically blocks the pores of K + channels and is an agent standardly used in electrophysiology for specific K + channel blockade without acute toxicity to normal brain tissue (Walz et al., 2002) . When compared with equimolar sodium chloride, controlling for changes in chloride content and overall osmolarity, we found that 10 mM CsCl reduced DIPG cell viability in all four DIPG cell cultures tested ( Figures 5D and S4A ). Interestingly, many K + channel genes exhibited strong downregulation with all three transcriptional therapies ( Figure S4B ), potentially accounting for part of the disruption of cell viability that these drugs display. As K + channels play roles in regulating membrane voltage and cell size changes during the cell cycle (Huang and Jan 2014), we hypothesized that their blockade may disrupt the ability of DIPG cells to progress through the cell cycle. After 10 hr of CsCl treatment, we did not observe a difference in the number of dead cells (Figures S4C-S4E) but rather a significant increase in the fraction of DIPG cells in G 2 /M with a decrease in the fraction of cells in S phase in two of the cultures tested ( Figure 5E ). Considering that we observed a decrease in viability in all four cultures tested, we believe that disruption of cell-cycle progression accounts only for part of the mechanism of K + channel blockade vulnerability in DIPG. Taken together, these data indicate that targeting K + channels disrupts DIPG cell growth and underscore K + channels as a target in DIPG.
EPH Receptor Signaling Plays a Role in DIPG Cell
Migration and Invasion GREAT analysis of shared SEs exhibited enrichment for genes controlling neuron projection and axon guidance ( Figure 4D) . A number of ephrin and EPH receptors were associated with SEs in all four patient-derived cell cultures ( Figure 6A ). EPH-ephrin signaling classically plays a role in axon pathfinding during normal neurodevelopment (Cramer and Miko, 2016; Hruska and Dalva, 2012; Xu and Henkemeyer, 2012) and represents a promising target in a number of CNS malignancies including medulloblastoma, ependymoma, and adult glioblastoma (Bhatia et al., 2015; Chen et al., 2015; Miao et al., 2015; Nakada et al., 2004 Nakada et al., , 2006 . To study the role of EPH-ephrin signaling in DIPG, we used LDN-211904 (Qiao et al., 2009 ), a selective inhibitor of forward EPH receptor signaling. Treatment with LDN-211904 did not substantially inhibit cell viability at concentrations less than 10 mM ( Figure S5A ), but 5 mM LDN-211904 drastically reduced cell invasion in all four DIPG cell cultures tested ( Figures  6B and S5B ). Furthermore, EPH blockade resulted in a dramatic, dose-dependent reduction in both SU-DIPG-XVII invasion (Figure 6C) and SU-DIPG-IV migration ( Figure 6D ) in a 3D Matrigel spheroid assay (Vinci et al., 2013 . Many of the EPH receptors and ephrins expressed by SU-DIPG-VI and SU-DIPG-XIII-P did not show downregulation with panobinostat or JQ1 (Figure S5C ). This suggests that additional therapy beyond HDAC or bromodomain inhibition would be needed to clinically target the effect of these signaling molecules on DIPG invasion.
Overall, we show here that blockade of EPH receptor signaling significantly reduces DIPG cell migration and invasion in vitro. EPH-ephrin signaling may represent an important pathogenic mechanism facilitating the diffuse and invasive spread of DIPG throughout the brainstem and, in most cases of DIPG, throughout much of the brain (Caretti et al., 2014) .
Panobinostat and THZ1 Disrupt Super-enhancer Biology
We found the set of SE-associated genes in SU-DIPG-VI and SU-DIPG-XIII-P to be enriched in the set of downregulated targets of both JQ1 and THZ1 ( Figures S6A and S6B) , consistent with previous findings Chipumuro et al., 2014; Lové n et al., 2013) , as well as panobinostat. As panobinostat increases H3K27me3 levels (Grasso et al., 2015) , we hypothesized that panobinostat may disrupt the H3K27Ac Please cite this article in press as: Nagaraja et al., Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma, Cancer Cell (2017) , http:// dx.doi.org/10.1016/j.ccell.2017.03.011 (legend continued on next page) mark at SEs. Consistent with this notion, H3K27Ac ChIP-seq following 24 hr of panobinostat treatment resulted in reduced enrichment of H3K27Ac at SEs (Figures 7A and 7B) . When examining all H3K27Ac peaks, we observed that panobinostat reduced H3K27Ac density selectively at the strongest regions in control cells ( Figure 7C) , with most peaks showing little change. The genes associated with these regions showed enrichment for the top panobinostat target genes ( Figures S6C  and S6D) , consistent with the proposed mechanism of panobinostat. When we examined the distance of these panobinostat target genes from the nearest TSS, we saw a large proportion of the sites located distal to any TSS ( Figure 7D ), suggesting that panobinostat disrupts H3K27Ac at both enhancer and promoter regions.
Finally, to identify core regulators of DIPG malignant state, we looked for SE-associated genes strongly disrupted in both SU-DIPG-VI and SU-DIPG-XIII-P with panobinostat (at least 2-fold) or THZ1 treatment (at least 8-fold; Figures 7E and S6E ). Fortyeight shared panobinostat targets were associated with an SE in both SU-DIPG-VI and SU-DIPG-XIII-P and 41 shared THZ1sensitive genes were linked to SEs in both cell cultures (Table  S5 ). We believe these sets of genes to be fundamental to DIPG biology. Intriguingly, these gene sets also contained a number of genes involved in axonal guidance (NAV1, SEMA4C; Maes et al., 2002; Martínez-Ló pez et al., 2005; Maier et al., 2011) , neurite outgrowth (NINJ1; Araki et al., 1997; Araki and Milbrandt, 1996) , synapse formation (LRFN4; Mah et al., 2010) , and glutamate receptor function (CNIH3, GRIK3; Herring et al., 2013; Strutz et al., 2001 ; Figure S6F ). These genes classically associated with neuronal communication suggest that DIPG cell interaction with neurons in the tumor microenvironment may be central to DIPG biology, reinforcing the notion that disruption of neuron-glioma interactions represents a prime target for therapeutic development (Venkatesh et al., 2015) .
DISCUSSION
No progress has been made in extending life for children with DIPG since the introduction of radiotherapy nearly four decades ago. However, a surge in DIPG research in recent years may prove to turn the tide. Comprehensive genomic studies identified the oncohistone H3K27M as the hallmark of pediatric gliomas affecting the midline of the CNS (Wu et al., 2012; Schwartzentruber et al., 2012; Khuong-Quang et al., 2012; Gessi et al., 2015; Shankar et al., 2016) . Central to DIPG oncogenesis (Funato et al., 2014) , the presence of H3K27M mutant histones alters the function of the PRC2 complex responsible for H3K27 trimethylation (Lewis et al., 2013) and results in broad dysregulation of transcription (Chan et al., 2013) . The creation of patientderived DIPG cell culture and orthotopic xenograft models has allowed for preclinical drug testing studies, revealing epigenetic therapies, such as histone demethylase inhibition (Hashizume et al., 2014) and HDAC inhibition with panobinostat (Grasso et al., 2015) as promising therapeutic strategies. Panobinostat was subsequently taken to phase I trial for children with DIPG (NCT02717455). While panobinostat may ultimately prove to be of clinical utility, it was clear from the preclinical studies that the best hope for this agent would be a temporary reprieve from tumor growth (Grasso et al., 2015; Hennika et al., 2017) , as resistance to mono-agent therapy does develop (Grasso et al., 2015) . The present study represents an effort to identify a combination strategy focused on complementary modulation of H3K27M-related transcriptional aberrations that would extend and improve upon the efficacy of panobinostat alone.
The data presented here demonstrate that DIPG is vulnerable to disruption of transcription both in vitro and in vivo. As previously shown, transcriptional inhibition mediated by JQ1 bromodomain inhibition impedes DIPG cell viability in vitro (Taylor et al., 2015) . We expand upon this finding by examining a range of bromodomain inhibitors and by demonstrating BRD4 as the key target using shRNA-mediated BRD4 knockdown. Our findings are consistent with a predicted role for BRD4 in H3K27M transcriptional pathology, based on the observation that Brd1 and Brd4 are associated with H3K27M-containing nucleosomes in a Drosophila model of H3K27M expression (Herz et al., 2014) . While more potent bromodomain inhibitor compounds exhibiting better brain penetration are needed for clinical translation of these findings, bromodomain inhibition may be an effective clinical therapy when the appropriate drugs are available. However, it is important to note that bromodomain inhibition appears cytostatic rather than cytocidal and that DIPG cells resistant to HDAC inhibition also exhibit concomitant resistance to bromodomain inhibition.
Disruption of transcription through CDK7 inhibition using THZ1 also impairs DIPG cell viability. The effect of CDK7 inhibition is cytocidal, and THZ1 therapy results in a modest increase in survival in a patient-derived DIPG xenograft model. However, CDK7 inhibitors with better brain penetration are needed for optimal clinical translation. Transcriptional inhibition via either BRD4 or CDK7 blockade shows therapeutic synergy with HDAC inhibition using panobinostat, and panobinostat-resistant DIPG cells retain vulnerability to THZ1. Thus, a combination strategy may prove to be of clinical utility when brain-penetrant transcriptional inhibitor compounds are available for clinical use or with alternative delivery strategies such as direct intratumoral infusion using convection-enhanced delivery.
Transcriptomic analyses following treatment with single and combinatorial panobinostat, JQ1, and THZ1 therapy provided insights as to how these epigenetic modifying agents disrupt gene expression. SE-associated genes were preferentially disrupted (C) Filled-in rectangles represent association with an SE in the indicated cell culture. Expression percentiles shown for mean expression value in either the four cell cultures indicated or SU-DIPG primary tumor samples published in Grasso et al. (2015) . For genome tracks shown, the x axis represents genomic position and y axis shows normalized reads per million (rpm). Black bars represent SE calls. (D) Patient-derived DIPG cultures were treated with 10 mM cesium chloride or sodium chloride for 3 days. Cell viabilities were normalized to NaCl controls; ****p < 0.001 for all data shown. (E) FACS cell-cycle analysis of DIPG cultures treated with 10 mM NaCl or CsCl for 10 hr before addition of EdU for 1 hr. Data are shown as proportion of cells in G 2 /M normalized to NaCl control. *Adjusted p < 0.05. Data in (D) and (E) are presented as mean ± SEM (n = 3). Student's t test was performed with Holm-Sidak correction. See also Figure S4 . (legend continued on next page) by all three therapies, and the H3K27Ac mark was lost at SEs following panobinostat treatment. We found that the top targets JQ1 and panobinostat were similar, potentially explaining our finding that panobinostat-resistant cells also display functional resistance to JQ1. By contrast, the set of genes identified as the top targets of THZ1 is only mildly inhibited by panobinostat or JQ1 treatment. As BRD family proteins couple activating histone marks to transcription (Wu and Chiang, 2007; LeRoy et al., 2008; Rahman et al., 2011) , we hypothesize that JQ1 and panobinostat may synergistically inhibit DIPG viability through orthogonal disruption of a common set of core genes, with JQ1 disrupting BRD4 activity at active histone marks and panobinostat restoring K27me3 at the same set of marks. By contrast, the set of genes disproportionately downregulated by THZ1 treatment are largely non-overlapping with the targets of panobinostat, and synergy may be achieved in combinatorial treatment by disrupting a larger overall number of genes than in single therapy.
To elucidate the chromatin landscape of DIPG, we performed ChIP-seq analyses of four patient-derived cell cultures. As nearly 80% of DIPG patients exhibit the K27M mutation in H3.3 or H3.1 (Khuong-Quang et al., 2012; Schwartzentruber et al., 2012; Wu et al., 2012) , which has been shown to cause global histone hypomethylation (Bender et al., 2013; Lewis et al., 2013) , the location of activating histone marks such as H3K27Ac may reveal genes that fail to undergo suppression during development and lead to tumor formation. Identification of SEs in DIPG provides insights into the genes maintaining the malignant state of DIPG as well as insights regarding the cell of origin. These analyses revealed a large number of oligodendroglial lineage genes associated with SEs in DIPG, including PDGFRA, OLIG1, OLIG2, NKX2.2, CSPG4, and SOX10 among others, as well as several genes marking an early neural precursor state, such as SOX2 and NES, supporting a leading hypothesis that the cell of origin of DIPG may be an early oligodendrocyte precursor cell (Monje et al., 2011; Tate et al., 2015) .
The SE analyses highlighted numerous genes classically involved in neurodevelopment or neuronal communication, underscoring the recently demonstrated importance of neuronglioma interactions (Venkatesh et al., 2015) and the emerging concept that pediatric gliomas hijack and recapitulate mechanisms of development. Prominent were axon pathfinding genes, such as a number of EPH receptors and ephrins. Functional analyses demonstrated that this canonical axon pathfinding pathway plays a robust role in DIPG cell migration and invasion. These findings are consistent with the invasion-promoting role of the EPH-ephrin pathway in adult gliobastoma (Nakada et al., 2004 (Nakada et al., , 2006 Miao et al., 2015) . We also found a large number of K + channel genes associated with SEs and demonstrated that, like several other cancers (Sun et al., 2016) , DIPG cells are vulnerable to K + channel blockade. These genomic findings provide a deeper understanding of DIPG pathobiology and elucidate potential targets for DIPG therapy. Although the number of potential targets dysregulated in DIPG suggests that epigenetic therapies that simultaneously disrupt aberrant expression of numerous target genes may be required as a part of any effective therapeutic strategy, some of the genes identified as upregulated and functionally important, such as EPH-ephrins, were not downregulated by the transcriptional inhibitors studied here and may require targeted therapy.
In summary, the data presented here demonstrate that disruption of transcription is a promising therapeutic strategy for DIPG when drugs with sufficient brain penetration are developed, particularly when administered together with an HDAC inhibitor. DIPG SE analyses support the hypothesis that the cell of origin for DIPG is a precursor cell in the oligodendroglial lineage and uncover several vulnerabilities of DIPG, elucidating fundamental pathological mechanisms promoting DIPG growth and invasion.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: LDN-211904 (5 mM) . Invading cell quantification was normalized to mean DMSO invasion. ****p Values versus DMSO: SU-DIPG-IV p = 0.0006, SU-DIPG-VI p = 0.0003, SU-DIPG-XIII-P p = 0.0004, SU-DIPG-XVII p = 0.0004. (C) (Left) Quantification of invasion distance of SU-DIPG-XVII cells treated with LDN-211904 at the concentrations indicated or DMSO control. Invasion distance normalized to day-0 distance for each sphere. p values of DMSO versus 5 mM LDN-211904: 24 hr, *p = 0.0311; 48 hr, ***p = 0.0005; 72 hr, ***p = 0.0001. in at least triplicate and then subjected to drug treatment as indicated. Cell viability was then measured by using Celltiter Glo assay (G7571, Promega, WI, USA), and data were collected on a TECAN Infinite 200 plate reader. For testing combinatory effects of two drugs, the cells were treated with each drug individually or in combination before subjecting to Celltiter Glo assay. CalcuSyn software (Biosoft, Cambridge, UK) was used to calculate the combination index (CI). CI less than 1.0 was considered to be synergistic.
Proliferation, Apoptosis, and Cell Cycle Assays
Cell proliferation and cell cycle phase was measured by using the Click-iT EdU Alexa Fluor 488 or 647 Flow Cytometry Assay Kit (Invitrogen, CA, USA). EdU+ population represented the proliferating cell population. Cell apoptosis was measured by using Annexin V-FITC Apoptosis Detection Kit II (556570, BD Biosciences, CA, USA) with some minor modifications. DAPI was used instead of PI. Cell cycle analysis additionally used LIVE/DEAD Near-IR (Life Technologies, L10119) to mark dead cells and DAPI to label nuclei after fixation and permeabilization. FACS analyses were performed by using BD Fortessa FACS machine (BD Biosciences, CA, USA). The data were analyzed using Flowjo software (FlowJo, LLC, OR, USA).
Lentivirus Preparation and Infection
Two shRNA expressing lentiviral constructs against human BRD4 (TRCN0000021425 and TRCN0000021426) from the RNAi consortium human collection were purchased from Sigma. Lentiviral particles were generated by co-transfection of lentiviral expressing constructs with packaging plasmids (pDelta 8.92 + VSV-G) into 293T cells, and then concentrated by polyethylene glycol (PEG) precipitation method. For lentiviral infection, dissociated DIPG cells were incubated with shRNA expressing lentivirus for 16 h before replacing with fresh medium. Puromycin (0.5 ug/ml) was added to select positively infected cells for further experiments at 48 hours post infection. For in vivo xenograft experiments, no puromycin selection was performed.
Western Blotting
Cells were lysed in RIPA Buffer with 1mM PMSF, protease inhibitor cocktail, 1mM sodium orthovanadate, (Santa Cruz Biotechnology sc-24948) and protein concentration was calculated using PierceÔ BCAÔ Protein Assay (Thermo ScientificÔ). Samples were diluted with 1 volume to 2X Laemmli Sample Buffer (Novex), 20% 2-mercaptoethanol. Gel electrophoresis was performed using SDS-PAGE and proteins were transferred to Immun-Blot PVDF Membrane (BioRad) using Mini-PROTEAN Tetra Cell (BioRad). Membranes were incubated with following primary antibodies for 16-20 hours at 4 C: RNAPII (1:100, Santa Cruz Biotechnologies #sc-899), RNAPII-CTD-SER2 (1:10,000, Bethyl #A300-654A-M), RNAPII-CTD-SER5 (1:2000, Bethyl #A304-408A-M), RNAPII-CTD-SER7 (1:500, Cell Signaling 13780S), CDK7 (1:10,000, Bethyl #A300-405A), Beta-Actin (1:2000, Cell Signaling #4970S), BRD4 (1:5000, Bethyl #A301-985A100), Beta-Tubulin (1:5000, Abcam #ab6046).
LC-MS/MS Analysis of Tissue and Serum Concentration
Tissues samples were weighed and 1 volume of bullet blender beads (Next Advance) and 3 volume of Milli-Q water were added. Tissues were homogenized by a bullet blender (Next Advance) at 4 C according to manufacturer's instruction. The neat stock solutions of THZ1, its internal standard (IS) mutant-EGFR-inhibitor (ChemScene, Cat. No.: CS-2099), OTX015 and its IS CPI-203 (ApexBio, Cat. No.: B1081) were prepared in DMSO and further diluted in 50% methanol to prepare spiking solutions. For spiked standard curve, 25 ml of THZ1 spiking solutions (5 ng/ml-500 ng/ml) or OTX015 spiking solutions (1 ng/ml-500 ng/ml) was mixed with 25 ml of their corresponding IS (100 ng/ml) and 25 ml of blank tissue homogenate or serum. For samples, the spiking solution was replaced by 25 ml of 50% methanol to make up the volume. After vortexing all standards and samples, 150 ml of methanol/acetonitrile 20:80 (v/v) was added to the mixture and vortexed vigorously for 1 min followed by centrifugation at 3,000 g for 10 min. The supernatant was diluted 3 times with Milli-Q water.
The LC-MS/MS system consists of a QTRAP 4000 mass spectrometer (AB SCIEX) coupled to a Shimadzu UFLC system. LC separation was carried out on a Dionex C18 column (100 mm 3 2.1 mm, 5 mm) at room temperature for both compounds. The analysis time was 2 min. The injection volume was 10-25 ml. For THZ1, isocratic elution was carried out with a mobile phase composed of 35% water and 65% acetonitrile with 0.1% of formic acid and 5 mM of ammonium acetate and a flow rate of 0.3 ml/min. For OTX015, isocratic elution was used with a mobile phase composed of 30% water and 70% acetonitrile with 0.1% of formic acid and a flow rate of 0.4 ml/min. The mass spectrometer was operated in the positive mode with multiple-reaction monitoring (MRM). The following MRM transitions were used: THZ1 (m/z 566.2/186.0), IS for THZ1 (m/z 520.4/72.0), OTX015 (m/z 492.3/383.1) and IS for OTX015 (m/z 400.2/383.1). Data acquisition and analysis were performed using the Analyst 1.6.1 software (AB SCIEX).
ChIP and Library Preparation
Cells were fixed with 1% formaldehyde for 10 minutes at room temperature. Cross-linking was quenched using 0.125 M glycine for 10 minutes before cells were washed twice with PBS. Cross-linked pellets were frozen with dry-ice ethanol and stored at -80 C. Two biological replicates were collected for each cell culture.
Pellets were thawed on ice before cell membrane lysis in 5 mL LB1 (50 mM HEPES pH 8.0, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, 1 mM PMSF, Roche protease inhibitors 11836170001) by rotating for 10 min at 4 C. Nuclei were pelleted at 1350xg for 5 minutes at 4 C. Nuclear lysis was performed in 5 mL LB2 (10 mM Tris-Cl pH 8.0, 5 M, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1 mM PMSF, Roche protease inhibitors) by rotating for 10 min at room temperature. Chromatin was pelleted at 1350xg for 5 minutes at 4 C and resuspended in 1.5 mL LB3 (10 mM Tris-Cl pH 8.0, 100 mM NaCl, 1 mM EDTA,
